Table 1.
Baseline Characteristics
| Variable | Never Smokers | Former Smokers | Current Smokers | P value* |
|---|---|---|---|---|
| Total patients (%) | 2937 (46) | 2554 (40) | 929 (14) | |
| Age at study entry | 0.0001 | |||
| Mean (SD) | 62.7 (6.0) | 63.2 (6.1) | 61.7 (5.8) | |
| Median (IQR) | 63 (58–67) | 63 (59–68) | 62 (57–66) | |
| Ethnic group (%) | 0.599† | |||
| White | 2690 (92) | 2351 (92) | 846 (91) | |
| Black | 60 (2) | 39 (2) | 20 (2) | |
| Other | 187 (6) | 164 (6) | 63 (7) | |
| Geographic region (%) | <0.001 | |||
| US/Canada | 675 (23) | 698 (27) | 180 (19) | |
| Europe | 1772 (60) | 1376 (54) | 575 (62) | |
| Other | 490 (17) | 480 (19) | 174 (19) | |
| Body mass index | 0.0001 | |||
| Mean (SD) | 27.1 (3.6) | 27.8 (3.8) | 26.9 (3.9) | |
| Median (IQR) | 26.4 (24.7–29.1) | 27.3 (25.1–29.8) | 26.4 (24.4–28.8) | |
| Suspicious DRE (%) | 110 (4) | 91 (4) | 40 (4) | 0.594† |
| Prostate volume, median (IQR) | 43.7 (33.1–56.0) | 43.8 (33.9–56.9) | 41.3 (31.7–56.2) | 0.0041 |
| Median PSA (IQR) | 5.7 (4.4–7.3) | 5.7 (4.4–7.3) | 5.7 (4.3–7.4) | 0.937 |
| Biopsy Gleason score (%) | 0.453† | |||
| 2–6 | 473 (71) | 405 (69) | 130 (66) | |
| 3+4 | 141 (21) | 120 (21) | 51 (30) | |
| ≥4+3 | 54 (8) | 57 (10) | 16 (8) | |
| Pack-Years, median (IQR) | 0 | 18 (8–30) | 25 (13–40) | 0.0001 |
| Treatment Arm (%) | 0.612 | |||
| Placebo | 1475 (50) | 1310 (51) | 481 (52) | |
| Dutasteride | 1462 (50) | 1244 (49) | 448 (48) |
Abbreviations: PSA (prostate specific antigen), SD (standard deviation), IQR (interquartile range)
*
P value by Kruskal-Wallis, except where noted.
†
P value by χ2